Skip to main content
. 2019 Jul 31;2(2):91–96. doi: 10.1016/j.jimed.2019.07.006

Table 3.

Tumor response according to the mRECIST.

Outcome HAIC with raltitrexed and oxaliplatin post-TACE
DCRa 75.7%28
ORRb 54.1%20
CR 8.1%3
PR 46.0%17
SD 21.6%8
PD 24.3%9

mRECIST: modified Response Evaluation Criteria in Solid Tumors; DCR: disease control rate; ORR, overall response rate; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.

a

DCR was calculated as CR ​+ ​PR ​+ ​SD.

b

ORR was calculated as CR ​+ ​PR.